Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Virology. 2015 Jul 1;484:276–287. doi: 10.1016/j.virol.2015.06.014

Figure 2. Redoxal and lomofungin inhibit HIV-1 replication in PBMCs.

Figure 2

A. Antiviral activity against HIV-1 replication in PBMCs. Redoxal and lomofungin were evaluated in dose-response assays using a high-test concentration of 100 μM and half-log dilutions. AZT was included as a positive control antiviral compound. Treated PBMCs were infected with HIV-1Ba-L isolate and 7 days post-infection virus replication and cell viability were measured by RT and MTS assays, respectively. Calculated values of the IC50, TC50, and therapeutic index of the compounds are shown. B. Redoxal exhibits broad antiviral activity against replication of diverse HIV-1 isolates in PBMCs. Antiviral activity against replication of three HIV-1 isolates in PBMCs. Redoxal was evaluated in dose-response assays using a high-test concentration of 100 μM and half-log dilutions. Treated PBMCs were infected with three HIV-1 isolates: Ba-L, 89BZ167, and 91US001. Seven days post-infection virus replication and cell viability were measured by RT and MTS assays, respectively. AZT served as the positive control antiviral compound. Calculated values of tested compounds’ IC90, IC50, TC50 and therapeutic index are shown. Shown in A and B are percentage of virus replication and cell viability in compound-treated cells relative to untreated controls. Results are representative of 3 independent experiments each done in triplicate (upper panel; means of triplicate samples from independent wells ± SD).